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Background: Polypharmacy is a well-established risk factor for falls, and these are
one of the major health problems that affect the quality of life as people age. However,
the risk of mobility and cognitive impairments consecutive to polypharmacy has been
little addressed, despite the association between these adverse outcomes and falls.
Moreover, the rare polypharmacy cut-offs were all but one arbitrarily determined.
Objective: Studying relationships between polypharmacy and both mobility and
cognitive impairments, and statistically determining a cut-off point in the number of
medicinal molecule beyond which polypharmacy has deleterious consequences with
respect to mobility and cognitive impairment.
Methods: We enrolled 113 community-dwelling adults aged 55 years and older
with a fall history, with or without injury, in the previous year. We carefully collected
information about daily medicinal molecules taken. We assessed basic mobility and
global cognition with the Time-Up-and-Go and the Montreal Cognitive Assessment
(MoCA) test, respectively (clinicaltrials.gov NCT02292316).
Results: Timed-Up and Go test and MoCA scores were both significantly correlated
with the number of molecule, used. Receiver Operating Characteristic curves indicate,
with high prediction (p < 0.002), that daily consumption of five or more molecules is
associated with risk for both impaired mobility and global cognition. These relationships
were independent of the number of comorbidities and of the pharmacological class.
Conclusion: Community-dwelling adults aged 55 years and older who take five or more
daily medicinal molecules are at high risk for both mobility and cognitive impairments.
Physicians and patients should be aware of these new findings, especially when there
are multiple prescribers involved in the care of the patient.
Keywords: polypharmacy, cut-off, mobility, gait, cognition, middle age, aging
INTRODUCTION
Some drugs are well-known for increasing the risk of falling, especially psychotropics (Hartikainen
et al., 2007). Concomitant use of several pharmacological molecules, here called polypharmacy, is
also incriminated in falls regardless of their pharmacological class (Tinetti et al., 1988; Ambrose
et al., 2013; Fried et al., 2014) because of the deleterious drug–drug interactions that result from
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interferences between pharmacokinetic and pharmacodynamic
properties of the different drugs (Chen et al., 2014). The
more drugs people take, the more drug–drug interactions occur
(Johnell and Klarin, 2007), and the higher the fall risk is (Kojima
et al., 2011). Nevertheless, adverse effects of polypharmacy are
seldom taken into consideration by the physicians, partly because
of lack of awareness.
Gait and cognitive disorders are two other major risk factors
for falls in older adults (Tinetti et al., 1988; Ambrose et al., 2013).
However, the number of medicinal molecules that can result in
mobility and cognitive impairment has rarely been addressed.
A negative linear relationship has previously been reported
between the number of medications used and a composite score
of balance measures (Agostini et al., 2004). Participants taking
five or more medications showed worsened functional abilities
over a 7-year follow-up (Pugh et al., 2007). One of the rare studies
in the cognitive field showed that incidence of dementia increases
steadily with the number of medications used (Lai et al., 2012).
The only study that used the Receiver Operating Characteristic
(ROC), a powerful tool for risk prediction, to search for a number
of medications that could predict cognitive impairment could not
find a cut-off value that led to accurate prediction (Gnjidic et al.,
2012).
Adverse effects of polypharmacy on dynamic balance and
cognition were all observed in populations of over 65 years
(Agostini et al., 2004; Pugh et al., 2007; Gnjidic et al., 2012;
Lai et al., 2012). Fall risk has, however, been associated with
the use of polypharmacy when the study population included
younger individuals of 55–65 years (Ziere et al., 2006). This
is an important finding since many younger adults are also
polymedicated and that occurrence of adverse health outcomes
associated with polypharmacy would be even more worrying if
occurring so early in life.
The objective of the present study was thus to determine
whether, and to what extent, polypharmacy could lead to
mobility and cognitive impairments. This was performed in
two ways in community-dwelling adults aged 55 years and
older: (i) by exploring the relationships between the number of
pharmacological molecules taken and both basic mobility and
cognitive performance; and (ii) by determining whether there is
an optimal number of molecules that could discriminate risk for
mobility and cognitive impairment using statistical method for
risk prediction.
MATERIALS AND METHODS
Patients
We enrolled 113 individuals over 55 years old who all had
experienced one or more falls, either with or without injury,
in the year prior to the study. We recruited them among
community-dwelling older adults through official bulletin boards
at the University hospital in Caen (France) and advertisements in
medical offices over a 3-year period. Exclusion criteria assessed
by the physicians were: a high-energy fall (e.g., fall down the
stairs or from collision), inability to walk for 15 m without
help, pathologies that affect posture, drinking more than 21 units
of alcohol per week (14 for women), and impaired vision
(acuity < 6/10).
The present study was approved by the Lower Normandy
Ethics Committee (no. 2011A00556-35; clinical trial registration
number: NCT02292316). Each participant provided written
informed consent.
Outcome Measures
We collected information about drugs, vitamins, and
supplements taken via medical prescriptions which was
confirmed by history taking during the clinical examination.
We used the total number of prescribed molecules to estimate
medication exposure (e.g., two molecules were counted in case
of the combination of two molecules in a single tablet), and
the Kaplan–Feinstein scale (Kaplan and Feinstein, 1974) to
determine the number of comorbidities.
We assessed basic functional mobility with the Timed-Up and
Go test (TUG) that requires standing up from an arm chair,
walking 3 m, turning, walking back to the chair, and sitting down.
The task was performed twice at a comfortable pace, and we
recorded the shortest time to complete the task. We measured
global cognition with the Montreal Cognitive Assessment test
(MoCA; Nasreddine et al., 2005), a 30-point test that covers
six cognitive domains: visuospatial/executive functions, naming,
attention, abstraction, recall, and orientation. Cut-off score
for impairment was based on the normative reference values
corrected for age for the TUG (Bohannon, 2006), and set at
26/30 for the MoCA (Nasreddine et al., 2005). The experimenters
who performed the gait and cognitive evaluation were blind to
participants’ medical treatment.
Statistical Analysis
We used adjusted Pearson correlations to analyze relationships
between the number of pharmacological molecules taken and
mobility score, cognitive score and number of comorbidities.
Adjustment variables were age and body mass index (BMI) for
the correlations with TUG score, and age only with those with
the MoCA score that already takes into account education level.
We performed ROC analyses on TUG and MoCA scores
(normal vs. impaired) to determine whether there is an optimal
cut-off value for the number of molecules that could be
responsible for cognitive and mobility impairments. The area
under the ROC curve (AUC) provides a measure of accuracy
of the prediction. We then performed several analyses using the
optimal cut-off values thus obtained. First, we computed analyses
of variance (ANOVAs) to compare TUG score, MoCA score, and
the number of psychotropic, antihypertensive, opioid analgesic
and others molecules between the participants taking fewer and
“as many or more” molecules than the cut-off value. We verified
the conditions of validity with Levene’s test. Second, we explored
the relationships between the number of molecules prescribed
(≥cut-off vs. <cut-off) and (i) TUG score (impaired vs. normal),
(ii) MoCA score (<26 vs. ≥26), (iii) the comorbidities (cut-off
as obtained in the “Results” Section, and (iv) the interactions
between these three variables. We performed both univariate
and multivariate logistic regressions on backward selection
method. We selected the variables based on the likelihood score
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statistic, and the adjustment variables were age and BMI when
appropriate. We performed all analyses with IBM R©SPSS R©22.0
software.
RESULTS
Table 1 describes the characteristics of the study population.
Mean TUG and MoCA scores were 9.39 ± 3.24 s and
26.47 ± 3.73, respectively, and the number of participants with
impaired TUG and MoCA scores was 39 and 27, respectively.
The number of pharmacological molecules used was significantly
correlated with the TUG score (R= 0.322; p< 0.001), the MoCA
score (R = −0.237; p < 0.004), and the number of comorbidities
(R = 0.322; p < 0.001). Regarding age of the study population,
34% were younger than 65 years old, and 38% were older than
75 years old.
Figure 1 that displays the ROC curves shows that the optimal
cut-off values was 4.5 for both impaired TUG and MoCA scores
with significant AUC for both scores(p = 0.002). Participants
who took five or more molecules were thus more likely to
show impaired TUG and MoCA performance than those who
took fewer molecules. When considering this cut-off value, the
ANOVAs showed that, compared to the participants taking fewer
than five molecules, those taking five molecules and more (1)
had significantly lower TUG and MoCA scores (p < 0.001 and
0.01, respectively, and (2) took twice as many antihypertensives
(0.56 ± 0.11 vs. 1.32 ± 0.12; p < 10−5), four times more
psychotropics (0.20 ± 0.07 vs. 0.56 ± 0.08; p < 10−5), 10 times
more opioid analgesics (0.02 ± 0.04 vs. 0.21 ± 0.04; p < 10−5),
and 2,5 times more molecules classified as others (1.40± 0.22 vs.
3.63± 0.25; p< 10−5). Besides, using the ROC methodology with
TABLE 1 | Characteristics of the study population (n = 113).
Age (mean ± SD) 69 ± 8.94
Women 89 (78.7%)
Years of education (mean ± SD) 11,19 ± 3.77
BMI (mean ± SD) 27,15 ± 5.34
Falls in the previous year (mean ± SD) 1.78 ± 1.99
Reason of falls
Health problema 7 (6.2%)
External eventsb 48 (42.5%)
Lack of attentionc 50 (44.2%)
Mixedd 8 (7.1%)
Falls with no injury 33 (29.2%)
Medication exposure 99 (87.7%)
Molecules taken (mean ± SD) 4.42 ± 3.58
Participants by number of molecules taken
0 molecule 14 (12.4%)
1 or 2 molecules 27 (23.9%)
3 or 4 molecules 22 (19.5%)
5 to 9 molecules 37 (32.7%)
≥10 molecules 13 (11.5%)
ae.g., faintness and fatigue; be.g., slippery floor, icy conditions, non-visible obstacle
in the dark, uneven ground, and inappropriate shoes; ce.g., while performing a
secondary task and missing a step; dcombination of two or three above reasons.
this cut-off of five molecules, we found that participants taking
five molecules and more were more likely to have at least two
comorbidities (AUC: 0.790 ± 0.044; p < 0.001). This cut-off of
two comorbidities was further used in the multivariate logistic
regression analysis.
Univariate analyses showed that: (i) 64.1% of participants with
impaired TUG and 33.8% with normal TUG were taking five or
more molecules (OR= 3.50, 95% CI = 1.55–5.89; p= 0.003); and
(ii) 59.5% of those with impaired MoCA scores and 35.2% with
normal MoCA were taking five or more molecules (OR = 2.71,
95% CI = 1.23–5.93; p = 0.013). Furthermore, multivariate
logistic regression analysis (Table 2) showed that impaired TUG
and MoCA scores, and having two or more comorbidities,
were each significantly associated with the use of at least five
daily pharmacological molecules; the interactions between TUG
score, MoCA score and the number of comorbidities were not
significant.
DISCUSSION
To our knowledge, this is the first study to show that impaired
mobility and global cognition, assessed here by the TUG and
MoCA test, respectively, are both significantly correlated with
the number of medicinal molecule taken. ROC curves indicate
that daily consumption of five or more molecules results in both
impaired TUG and MoCA scores. Logistic regression provides
evidence that the relationships between this polypharmacy
cut-off and mobility, and between polypharmacy cut-off and
cognition, are independent of the relation between mobility and
cognition, and of the number of comorbidities.
The poorer TUG score with the increased number of
medicinal molecules used confirms the linear relationship
between number of medications and impaired balance (Agostini
et al., 2004). Furthermore, the reduced basic mobility with
concomitant use of five or more medicinal molecules would be
consistent with the association of polypharmacy cut-off of five
drugs, arbitrary determined, with worsening of gait and balance
at 7-year follow-up (Pugh et al., 2007). The present study is the
first to define a polypharmacy cut-off value, of five medicinal
molecules, for adverse outcomes on functional mobility, as
assessed by a static and dynamic balance test, using statistical
methods. The significant AUC of the ROC curve indicates that
the prediction of impaired mobility when using five or more
molecules is very accurate. Finally, the logistic regression analysis
supports the validity of this cut-off value since it shows that
participants with impaired TUG scores are 3.5 times more likely
to be taking five or more pharmacological molecules.
The significant decrease in global cognition with the increased
number of medicinal molecules taken is a new finding. It
has only been reported that patients with dementia were
more likely to use a higher number of medications per
day than controls (Lai et al., 2012). Because participants
in the present study had essentially normal cognition, our
findings extend the deleterious effects of polypharmacy to
a mainly cognitively intact population. The prediction of
cognitive impairment when again taken five or more molecules
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FIGURE 1 | Each point on the ROC curve corresponds to a specific cut-off, with each cut-off having its own sensitivity and specificity. The optimal
cut-off is defined as the value, here that of the number of molecules, that provides the best combination of sensitivity and specificity. This optimal cut-off can be
identified as the intersection of the ROC curve with the diagonal. The area under the curve (AUC) is equal to 1 for perfect discrimination and 0.5 for an uninformative
cut-off point. The optimal cut-off value of the number of molecules was 4.5 for each ROC curve. MoCA, Montreal Cognitive Assessment; TUG, Timed Up and Go
test.
TABLE 2 | Results of the logistic regression analysis.
Multivariate logistic regression Number of molecules ≤5 vs. <5
OR 95% CI p-value
MoCA (<26) vs. MoCA (≥26) 3.153 1.187 – 8.373 0.021
TUG (–) vs. TUG (+) 2.753 1.046 – 7.249 0.040
Number of comorbidities (<2 vs. ≥2) 8.730 3.000 – 25.404 <10−3
MoCA, Montreal Cognitive Assessment; TUG, Timed Up and Go.
was again very good. Excessive polypharmacy (>10 drugs)
has been shown to be associated with decline in cognitive
capacity as measured by the Mini Mental State Examination
(MMSE) in persons over 75 years old (Jyrkkä et al., 2011).
However, Gnjidic et al. (2012) did not find evidence of
a polypharmacy cut-off that accurately predicted cognitive
disorders, as determined by a diagnosis of mild cognitive
disorders (MCI) or dementia in participants with impaired
MMSE. Discrepancy with the present findings could be explained
by the use of the MMSE, known to be less sensitive than
the MoCA, for detecting slight cognitive deficits (Nasreddine
et al., 2005). Finally, logistic regression analyses showed that
participants with impaired MoCA scores are almost three times
more likely to have been taking more than five molecules per
day than five or fewer. This is thus the first study that, to
our knowledge, identifies a polypharmacy cut-off for impaired
cognition.
Importantly, logistic regression analyses provide evidence
that the relationships between polypharmacy cut-off and
mobility, and between polypharmacy cut-off and cognition,
are independent of both the relation between mobility and
cognition, and the number of comorbidities. Noteworthy, all
pharmacological classes are concerned by the present findings
and not a specific class only. It should, however, be noted that the
participants of the present study who took five or more molecules
were the most likely to take drugs known to alter mobility
or cognition (antihypertensive, psychotropic, opioid analgesic
drugs. . .). Further investigations are thus required to determine
the specific involvement of each class of medicinal molecule in
people at risk for cognitive and mobility impairments.
Because our population was younger than those included in
most polypharmacy studies [34% between 55 and 64 years vs.
almost 100% ≥65 years (e.g., Agostini et al., 2004; Johnell and
Klarin, 2007; Pugh et al., 2007; Kojima et al., 2011; Gnjidic et al.,
2012; Lai et al., 2012, respectively), our findings highlight that
middle aged persons are also affected by the polypharmacy issue.
Only rare studies have addressed the issue of the risks of falling
(Ziere et al., 2006; Bennett et al., 2014), mobility impairments,
in particular during dual walking task (Pothier et al., 2014) or
polypharmacy (Bennett et al., 2014; Lu et al., 2015) at different
stages of life in older adults. Further investigations would thus
be useful for improving our understanding of the deleterious
effects of polypharmacy at different stages of adult life in order to
implement accurate strategies as soon as polypharmacy becomes
a risk to people.
One could argue that the present findings may not be relevant
for the general population since all participants had fallen in
the previous year. Nevertheless, our population is very similar
to the general population in many points: (i) a third did not
require a medical consultation since the fall was harmless; (ii)
an unavoidable external event was the cause of numerous falls
(34.5%); (iii) cognitive and gait abilities were both in the normal
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range [24% impaired MoCA score vs. 42% in community-
dwelling women over 65 years old (Liu-Ambrose et al., 2008);
mean TUG score of 9.39 s vs. 9.4 s in the same age group
in Bohannon’s meta-analysis (Bohannon, 2006)]; and (iv) the
daily number of drugs taken was similar in our sample and
in community-dwelling adults aged 60 years and older (4.4 vs.
4.5; e.g., Golden et al., 1999). The only difference from the
general population comes from the mode of recruitment since
we specifically searched for individuals who had fallen in the
previous year. Since one may assume that most people will
experience a fall during their life span, after sufficient time has
elapsed, one may gather all individuals who would undergo a fall.
Because 30–40% of the individuals older than 65 years fall every
year (Tinetti et al., 1988), it is thus likely that after our 3 years
of inclusion, we had collected a significant part of the general
population.
Second, the number of falls and related injury were not
considered in the statistical analysis because retrospective self-
report in older adults, as recorded in the present study,
often results in under-estimation of the true incidence of
falls (Cummings et al., 1988), and they were only 29.2% of
falls without injury, which limits the interest of intergroup
comparisons. The issue of recurrent falls and severity of the
falls will be addressed after the 2-years of follow-up presently in
progress.
Finally, although our sample size is relatively small, the results
of the multivariate logistic regression can be considered as robust
because the confidence intervals for the values of the TUG and
MoCA are relatively narrow despite this small sample size.
CONCLUSION
The present study indicates that the use of five or more
pharmacological molecules constitutes a risk for both mobility
and cognitive impairments in community-dwelling adults aged
55 years and older, at least in those who experienced a fall.
This would likely explain a significant number of falls that
occur in older adults, which would be supported by the same
polypharmacy cut-off in the number of medications reported
for the risk of falling (Gnjidic et al., 2012). This polypharmacy
cut-off of five or more molecules should thus be considered by
the physicians as a warning signal, especially when there are
multiple prescribers involved in the care of the patient. Despite
the obvious relation between polypathogy and polypharmacy
(Nobili et al., 2011) confirmed here, that makes health status
the first determinant of polypharmacy, numerous studies provide
evidence for possible reduction in the prescription of medication;
for instance, inappropriate medications, insufficient efficacy of
highly prescribed drugs and adverse drug–drug interactions
(Farrell et al., 2013; Chen et al., 2014). The finding that five
medicinal molecules and more are prescribed as soon as a patient
shows two pathologies highlights the disproportion between
polypathology and number of medicinal molecules taken. Thus,
although it may often be impossible to limit the number of
molecules used in patients with various and specific pathologies
such as after myocardial infarction, physicians and patients
should both be aware of these findings.
AUTHOR CONTRIBUTIONS
The study was designed by CC and CM. CC was responsible for
supervision of the study. PL, CM and PD did the medical visits
for inclusions and the collection of clinical data such as medical
treatments. They also provided expertise in rheumatology and
geriatrics for the results interpretation. M-LB and VL-B’s
pharmacological expertise contributed to the literature search
and the data interpretation. RM performed the advanced
statistical analysis, and thanks to his additional medical expertise,
also took an important part in the data interpretation. Gait
and cognitive data was collected and analyzed by AL and KP.
The paper was written by AL, KP, and CC, and all the authors
provided critical revisions of the manuscript for important
intellectual content.
FUNDING
This work as well as KP were supported by a grant from the
French Ministry of Health (PHRC Programme Hospitalier de
Recherche Clinique 2011 no. 2011-A00534-37). KP was also
supported by the Regional Council of Lower Normandy and the
GRAAL association (Groupe de Recherche sur les Affections de
l’Appareil Locomoteur).
ACKNOWLEDGMENTS
The authors would like to thank all the participants for their
time and cooperation, Dr. Valérie Caridroit and Dr. Thiphaine
Ciappuccini for their participation in the medical examinations,
Nicolas Bessot for his contribution to gait data acquisition
and involvement in preliminary investigations, Marion Hommet
for the neuropsychological assessment, Anita Jamet for her
contribution to the recruitment of the participants, and Valérie
Constans for English proofreading.
REFERENCES
Agostini, J. V., Han, L., and Tinetti, M. E. (2004). The relationship between number
of medications and weight loss or impaired balance in older adults. J. Am.
Geriatr. Soc. 52, 1719–1723. doi: 10.1111/j.1532-5415.2004.52467.x
Ambrose, A. F., Paul, G., and Hausdorff, J. M. (2013). Risk factors for falls
among older adults: a review of the literature. Maturitas 75, 51–61. doi:
10.1016/j.maturitas.2013.02.009
Bennett, A., Gnjidic, D., Gillett, M., Carroll, P., Matthews, S., Johnell, K., et al.
(2014). Prevalence and impact of fall-risk-increasing drugs, polypharmacy,
and drug–drug interactions in robust versus frail hospitalised falls patients: a
prospective cohort study. Drugs Aging 31, 225–232. doi: 10.1007/s40266-013-
0151-3
Bohannon, R. W. (2006). Reference values for the timed up and go test:
a descriptive meta-analysis. J. Geriatr. Phys. Ther. 2001, 64–68. doi:
10.1519/00139143-200608000-00004
Frontiers in Pharmacology | www.frontiersin.org 5 August 2016 | Volume 7 | Article 296
fphar-07-00296 August 30, 2016 Time: 15:32 # 6
Langeard et al. Polypharmacy Effect on Mobility and Cognition
Chen, Y., Zhu, L.-L., and Zhou, Q. (2014). Effects of drug
pharmacokinetic/pharmacodynamic properties, characteristics of medication
use, and relevant pharmacological interventions on fall risk in elderly patients.
Ther. Clin. Risk Manag. 10, 437–448. doi: 10.2147/TCRM.S63756
Cummings, S. R., Nevitt, M. C., and Kidd, S. (1988). Forgetting falls. The limited
accuracy of recall of falls in the elderly. J. Am. Geriatr. Soc. 36, 613–616. doi:
10.1111/j.1532-5415.1988.tb06155.x
Farrell, B., Merkley, V. F., and Thompson, W. (2013). Managing polypharmacy
in a 77-year-old woman with multiple prescribers. CMAJ 185, 1240–1245. doi:
10.1503/cmaj.122012
Fried, T. R., O’Leary, J., Towle, V., Goldstein, M. K., Trentalange, M., and Martin,
D. K. (2014). Health outcomes associated with polypharmacy in community-
dwelling older adults: a systematic review. J. Am. Geriatr. Soc. 62, 2261–2272.
doi: 10.1111/jgs.13153
Gnjidic, D., Hilmer, S. N., Blyth, F. M., Naganathan, V., Waite, L., Seibel, M. J., et al.
(2012). Polypharmacy cutoff and outcomes: five or more medicines were used to
identify community-dwelling older men at risk of different adverse outcomes.
J. Clin. Epidemiol. 65, 989–995. doi: 10.1016/j.jclinepi.2012.02.018
Golden, A. G., Preston, R. A., Barnett, S. D., Llorente, M., Hamdan, K.,
and Silverman, M. A. (1999). Inappropriate medication prescribing in
homebound older adults. J. Am. Geriatr. Soc. 47, 948–953. doi: 10.1111/j.1532-
5415.1999.tb01289.x
Hartikainen, S., Lönnroos, E., and Louhivuori, K. (2007). Medication as a risk
factor for falls: critical systematic review. J. Gerontol. A Biol. Sci. Med. Sci. 62,
1172–1181. doi: 10.1093/gerona/62.10.1172
Johnell, K., and Klarin, I. (2007). The relationship between number of drugs and
potential drug-drug interactions in the elderly: a study of over 600,000 elderly
patients from the Swedish Prescribed Drug Register. Drug Saf. 30, 911–918. doi:
10.2165/00002018-200730100-00009
Jyrkkä, J., Enlund, H., Lavikainen, P., Sulkava, R., and Hartikainen, S. (2011).
Association of polypharmacy with nutritional status, functional ability and
cognitive capacity over a three-year period in an elderly population.
Pharmacoepidemiol. Drug Saf. 20, 514–522. doi: 10.1002/pds.2116
Kaplan, M. H., and Feinstein, A. R. (1974). The importance of classifying initial
co-morbidity in evaluating the outcome of diabetes mellitus. J. Chronic Dis. 27,
387–404. doi: 10.1016/0021-9681(74)90017-4
Kojima, T., Akishita, M., Nakamura, T., Nomura, K., Ogawa, S., Iijima, K., et al.
(2011). Association of polypharmacy with fall risk among geriatric outpatients.
Geriatr. Gerontol. Int. 11, 438–444. doi: 10.1111/j.1447-0594.2011.00703.x
Lai, S.-W., Lin, C.-H., Liao, K.-F., Su, L.-T., Sung, F.-C., and Lin, C.-C. (2012).
Association between polypharmacy and dementia in older people: a population-
based case-control study in Taiwan. Geriatr. Gerontol. Int. 12, 491–498. doi:
10.1111/j.1447-0594.2011.00800.x
Liu-Ambrose, T. Y., Ashe, M. C., Graf, P., Beattie, B. L., and Khan, K. M.
(2008). Increased risk of falling in older community-dwelling women with
mild cognitive impairment. Phys. Ther. 88, 1482–1491. doi: 10.2522/ptj.200
80117
Lu, W.-H., Wen, Y.-W., Chen, L.-K., and Hsiao, F.-Y. (2015). Effect of
polypharmacy, potentially inappropriate medications and anticholinergic
burden on clinical outcomes: a retrospective cohort study. CMAJ 187, E130–
E137. doi: 10.1503/cmaj.141219
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V.,
Collin, I., et al. (2005). The Montreal Cognitive Assessment, MoCA: a brief
screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695–699.
doi: 10.1111/j.1532-5415.2005.53221.x
Nobili, A., Garattini, S., and Mannucci, P. M. (2011). Multiple diseases
and polypharmacy in the elderly: challenges for the internist of
the third millennium. J. Comorbidity 1, 28–44. doi: 10.15256/joc.
2011.1.4
Pothier, K., Benguigui, N., Kulpa, R., and Chavoix, C. (2014). Multiple object
tracking while walking: similarities and differences between young, young-
old, and old-old adults. J. Gerontol. B Psychol. Sci. Soc. Sci. 70, 840–849. doi:
10.1093/geronb/gbu047
Pugh, M. J. V., Palmer, R. F., Parchman, M. L., Mortensen, E., Markides, K.,
and Espino, D. V. (2007). Association of suboptimal prescribing and change
in lower extremity physical function over time. Gerontology 53, 445–453. doi:
10.1159/000119460
Tinetti, M. E., Speechley, M., and Ginter, S. F. (1988). Risk factors for falls among
elderly persons living in the community. N. Engl. J. Med. 319, 1701–1707. doi:
10.1056/NEJM198812293192604
Ziere, G., Dieleman, J. P., Hofman, A., Pols, H. A. P., van der Cammen, T. J. M.,
and Stricker, B. H. C. (2006). Polypharmacy and falls in the middle age and
elderly population. Br. J. Clin. Pharmacol. 61, 218–223. doi: 10.1111/j.1365-
2125.2005.02543.x
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Langeard, Pothier, Morello, Lelong-Boulouard, Lescure, Bocca,
Marcelli, Descatoire and Chavoix. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 6 August 2016 | Volume 7 | Article 296
